Bright Minds Biosciences Statistics
Total Valuation
DRUG has a market cap or net worth of $660.55 million. The enterprise value is $442.99 million.
| Market Cap | 660.55M |
| Enterprise Value | 442.99M |
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DRUG has 9.81 million shares outstanding. The number of shares has increased by 42.99% in one year.
| Current Share Class | 9.81M |
| Shares Outstanding | 9.81M |
| Shares Change (YoY) | +42.99% |
| Shares Change (QoQ) | +23.56% |
| Owned by Insiders (%) | 16.84% |
| Owned by Institutions (%) | 62.00% |
| Float | 5.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.99 |
| P/TBV Ratio | 2.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 81.48, with a Debt / Equity ratio of 0.00.
| Current Ratio | 81.48 |
| Quick Ratio | 81.10 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -642.68 |
Financial Efficiency
Return on equity (ROE) is -15.02% and return on invested capital (ROIC) is -10.56%.
| Return on Equity (ROE) | -15.02% |
| Return on Assets (ROA) | -10.44% |
| Return on Invested Capital (ROIC) | -10.56% |
| Return on Capital Employed (ROCE) | -9.98% |
| Weighted Average Cost of Capital (WACC) | 3.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$753,699 |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +127.29% in the last 52 weeks. The beta is -0.11, so DRUG's price volatility has been lower than the market average.
| Beta (5Y) | -0.11 |
| 52-Week Price Change | +127.29% |
| 50-Day Moving Average | 78.83 |
| 200-Day Moving Average | 73.25 |
| Relative Strength Index (RSI) | 38.65 |
| Average Volume (20 Days) | 445,404 |
Short Selling Information
The latest short interest is 805,672, so 8.21% of the outstanding shares have been sold short.
| Short Interest | 805,672 |
| Short Previous Month | 756,484 |
| Short % of Shares Out | 8.21% |
| Short % of Float | 15.72% |
| Short Ratio (days to cover) | 3.45 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.07M |
| Pretax Income | -19.60M |
| Net Income | -19.60M |
| EBITDA | n/a |
| EBIT | -22.07M |
| Earnings Per Share (EPS) | -$2.48 |
Balance Sheet
The company has $221.86 million in cash and $58,838 in debt, with a net cash position of $221.81 million or $22.61 per share.
| Cash & Cash Equivalents | 221.86M |
| Total Debt | 58,838 |
| Net Cash | 221.81M |
| Net Cash Per Share | $22.61 |
| Equity (Book Value) | 221.03M |
| Book Value Per Share | 22.53 |
| Working Capital | 220.98M |
Cash Flow
| Operating Cash Flow | -14.21M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 51,028 |
| Net Borrowing | -73,272 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRUG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.99% |
| Shareholder Yield | -42.99% |
| Earnings Yield | -2.97% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DRUG is $164.55, which is 158.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $164.55 |
| Price Target Difference | 158.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.
| Last Split Date | Jul 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |